T1D Exchange - QI Learning Session 2023: Improving Diabetes Outcomes, 11/14/2023 - 11/15/2023
This two-day, hybrid course will provide insights from multidisciplinary teams representing T1D Exchange QI Collaborative. The focus will include both pediatric and adult patients with type 1 and type 2 diabetes. Talks, panels, and breakouts will cover topics in quality care improvement of diabetes outcomes; patient education and disease management; comorbidities; device use; data analysis and data outcomes; and special considerations in co-production with patients and families. Time will be devoted to interactive abstract discussions regarding interventions, successes, and therapeutic challenges. Mount Sinai and NYU Langone will co-host the program and provide onsite clinical tours.
By the end of this learning session, we want participants to:
- Know: We are making a positive impact on diabetes through the contributions of our academic, industry, medical, and research partners.
- Feel: Energized that we have the tools to effectively mobilize clinical teams and optimistic about the resources shared across T1DX-QI through collaboration.
- Do: Co-produce and implement new PDSA cycles and share results with the QI Collaborative.
This activity has been designed to meet the educational needs of Endocrinologists, PCPs, pharmacists, physician assistants, nurses, nurse practitioners, and QI Specialists who are involved in the care and treatment of patients with Type 1 diabetes.
At the conclusion of this activity, participants will be able to:
- 1. Describe the future of novel therapies, interventions, quality improvements, and solutions to today’s diabetes care challenges.
- 2. Identify gaps in population health needs and state 3 ways that they can provide more equitable care over the next 2 years.
- 3. Apply the strategies of the T1DX-QI Equity Framework which can help to improve diabetes health outcomes and increase diabetes device access for BIPOC T1D and T2D patients.
- 4. Discuss expectations for patient care and patient engagement and describe ways to co-design care with patients and family members.
Blake Adams; Gina Agiostratidou, PhD, MBA; Guido Alacron, MD; Whitney Beaton, MD; Emily Breidbart, MD; Don Buckingham, MBOE, CPHQ; Rebecca Butler, LMSW; Rebecca Campbell, BS; Lily Chao, MD; Abha Choudhary, MD; Edelina Bustamante Cohen, MS, RD, CDN, CDCES; Emily Coppedge, NP, CDE; Sarah Corathers, MD; Anna Cymbaluk, MD; Sean DeLacey, MD; Emily DeWit, MASL; Sanjoy Dutta, Ph.D.; Donna Eng, MD; Rachel Fenske, PhD, RDN, CD, LDN; Veronica Figueredo, MD; Mary Pat Gallagher, MD; Ashley Garrity; Lauren Golden, MD; Amy Grant, DNP; Michael Harris, NICH, OHSU; Jeff Hitchcock; Jeniece Ilkowitz, RN; Manmohan Kamboj, MD; Toyetta Barnard-Kirk, MSW, LSW; Laurel Koester, MPH; Anne Koralova, PhD; Danny Kovarik, MBA; Sarah Lyons, MD; Faisal Malik, MD, MSHS; Allison Mekhoubad, DO; Jovan Milosavljevic, MD; Brian Miyazaki, MD; Ann Mungmode, MPH; Grace Nelson; Isabella Niu, MD; Ori Odugbesan, MD, MPH; Stephanie Ogburn; Amy Ohmer; Emma Ospelt, MPH; David Panzirer; Claire Petty, BA; Isabel Reckson, RD, CDE; Alissa Roberts, MD; Jennifeer Ruiz, RN; Janine Sanchez, MD; Jennifer Sarhis, MD; Viral Shah, MD; Allison Smego, MD; Inas Thomas, MD; Marissa Town, RN, BSN, CDCES; Meredith Wilkes, MD; Candice Williams, APRN; Trevon Wright, MHA
- Dr. Accachia is a speaker for Azurity Pharmaceuticals Inc.
- Dr. Agarwal is a consultant for Acumen, Beta Bionics Inc. and Medtronic Inc. He receives grant reasearch support from Dexcom.
- Dr. Akturk is a consultant and receives grant/research support from Dexcom, Mannlkind, Medtronic and Tandem Diabetes Care. .
- Dr. Albanese-O' Neill is a speaker for Insulet and Tandem Diabetes Care.
- Dr. Alonso is a consultant for Mannkind.
- Dr. Antal is a consultant for Bayer Pharmaceuticals.
- Dr. Clements receives grant/research support from Abbott Diabetes Care and Dexcom. He also is a consultant for Glooko.
- Dr. Cossen receives grant/reasearch support from IBSA Phrama Inc., Mannkind and Zealand.
- Dr. Dimeglio receives grant/research support from Dompe, Eli Lilly, Mannkind, Medtronic, Provention, and Zealand. She is a consultant for Abata, Eli Lilly, Merck and Vertex. She owns stock in Eli Lilly and has a patent application with Panbela.
- Dr. DeSalvo receives grant/research support and is a consultant for Insulet and is a consultant and speaker for Dexcom.
- Dr. Ebekozien receives employer grant/research support from Abbott, Dexcom, Eli Lilly, Jannsen, JDRF, Mannkind, Medtronic, and Vertex. He is also a consultant for Medtronic and Sanofi, and a speaker for Medtonic Diabetes, Sanofi and Vertex.
- Dr. Gupta organization receives research support from Diurnall Limited.
- Dr. Hannon receives grant/research support from Eli Lilly Inc. and Novo Nordisk and is also a consultant for Eli Lilly.
- Dr. Jones is a speaker for Medtronic.
- Dr. Lee is a consultant for Sanofi and Tandem Diabetes Care, and is also on Goodrx's medical advisory board.
- Dr. Levy is volunteer consultant for the Epic System Corporation.
- Dr. Maahs receives research support from the NIH and NSF and his institution has had research support from Dexcom. Dr. Maahs is a consultant for Abbott, the Helmsley Charitable Trust, Lifescan, Sanofi, Medtronic, Provention Bio, Kriya, and Bayer.
- Dr. O'Malley receives grant/researh support from Dexcom, Mannkind and Tandem Diabetes Care.
- Dr. Pasquel receives grant/researcg support from Dexcom, Ideal Medical Technologies, Insulet, Novo Nordisk and Tandem. He is also a consultant for Dexcom.
- Dr. Perkins receives grant/research support from Tandem Diabetes Care.
- Dr. Shah receives grant/research support from Alexion, Insulet, NovoNordisk, and Tandem Diabetes Care and is also a consultant for NovoNordisk, and Sanofi. He is also a speaker for Embecta, Insulet and Tandem Diabetes Care.
- Dr. Town's organization receives grant/research support from Abbott, Dexcom, Eli Lilly, Insulet, JDRF, Medtronic, Novo Nordisk, Provention Bio, Splenda, Tandem Diabetes, Walgreens, and Xeris.
- Dr. Steenkamp receives grant research support from Abbott Diabetes Care, Mannkind, Novo Nordisk, and Tandem Diabetes Care.
- Mr. Walton is a consultant advisor for Diatech Diabetes and Alertgy.
- Dr. Weinstock institution receives grant/research support from Amgen, DexCom, Diasone, Eli Lilly, Insulet, Novo Nordisk, Mannkind and Tandem Diabetes Care.
- Mr. Walton is a consultant for Diatech Diabetes and Alertgy.
Off label discussion of Amylin, SGLT2s, GLP-1s and metformin will be included on Tuesday, 11/13 in Breakout session 2.
Program Planning Committee
David Hansen, MD, CME Medical Course Director, receives grant/research support from Boehringer Ingelheim, Insulet, Eli Lilly and Medtronic.
The following members of the T1D Exchange planning committee have no relevant financial relationships to disclose:
- Sheila Dennely, RN - Nurse Planner and CNE Accreditation Advisor
- Holly Hardison, BS - Program Manager
- Nicole Rioles, MA; T1D Exchange’s Director of Clinical Partnerships and Population Health
TID Exchange's CME Course Director, receives grant/research support from Boehringer Ingelheim, Insulet, Eli Lilly and Medtronic.
The following planning committee members from Boston University School of Medicine’s Continuing Medical Education Office have no relevant financial relationships to disclose:
- Michael Burk, BS; Senior Program Manager
- Catherine Sullivan, MD; Boston Medical Center, Endocrinology; Independent CME Content Reviewer
Accreditor Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
ALL PROGRAMS, ACTIVITIES, AND MATERIALS PROVIDED BY Boston University CHOBANIAN & AVEDISIAN SCHOOL OF MEDICINE BARRY M. MANUEL CENTER FOR CONTINUING EDUCATION OR ITS ASSOCIATES ARE PROVIDED ON THE CONDITION THAT THEY BE USED SOLELY FOR EDUCATIONAL PURPOSES BY QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE CONTINUING EDUCATION PROGRAMS, ACTIVITIES OR MATERIALS. . IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Jointly Provided Accreditation
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and T1D Exchange. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University School of Medicine designates this live activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Contact Hours: 11.5, of which 5.25 are eligible for pharmacology credit.
- 11.50 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 11.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 11.50 ANCC
- 5.25 ANCC Pharmacology
- 11.50 Participation